October 26

Duke Survey Clinical trials: Research Conflicts of Interest Violate ethical Guidelines – UPI

Duke Survey Clinical trials: Research Conflicts of Interest Violate ethical Guidelines_UPI

Sun, 27 Oct 2002

A major Duke University survey of 108 U.S. medical schools reveals that medical institutions fail utterly to meet international standards aimed at ensuring the integrity of clinical research and the safety of the subjects. Conflicts of interest have derailed ethical conduct of research in academia because corporate sponsors control clinical trials and skew the findings. They do so by maintaining control over the entire process– including, the research design, subject selection, data collection and analysis, and select the findings that are published.

The Duke survey found that “…the institutions participating in our survey rarely required the presence of an independent executive committee, data and safety monitoring board, or publications committee…Such bodies can be important safeguards of integrity and safety in clinical trials.” [See: Schulman KA, et al, Provisions in Clinical-Trial Agreements, New England Journal of Medicine, Vol. 347, No. 17, Oct 24, 2002, pp. 1335-1341]

International standards were adopted by 500 scientific journal editors following a series of embarrassing disclosures that biased clinical trial reports had been published in the major scientific journals–though they lacked scientific integrity and failed to comply with ethical safeguards. The International Committee of Medical Journal Editors attempted to reclaim the integrity of the scientific literature.

UPI reports (below) that Dr. Drummond Rennie, a deputy editor at Journal of the American Medical Association, was not surprised (by the findings) “because this shows what an appalling state everyone was in. It takes years to changes things like this.”

But the lead Duke study author, Dr. Kevin A. Schulman, a professor of medicine, said the low compliance rate was a bit of a shock. Furthermore, he called the trend toward publishing selected portions of a multi-site trial, “salami science.” Such trials further erode patient protections because researchers at one site don’t know the findings or adverse events at the other.



Research contracts violate guidelines

From the Science & Technology Desk UPI Published 10/23/2002 5:39 PM

DURHAM, N.C., Oct. 23 (UPI) — A review of more than 100 contracts between academic research institutions and corporate sponsors found they repeatedly failed to adhere to international guidelines designed to protect the integrity of the research, a new study released Wednesday reveals.

Such a failure to follow these guidelines, which include items such as design of clinical trials, who has access to the clinical trial data and publication rights, could threaten research investigators and even patients, the study concludes.

Led by researchers at Duke University Medical Center and the Duke University School of Law in Durham, N.C., the study looked at 108 institutional members of the Association of American Medical Colleges. The study, which lasted from November 2001 to January 2002, examined the extent to which contracts between these institutions and industry sponsors complied with three key provisions put out by the International Committee of Medical Journal Editors.

The ICMJE guidelines are used by more than 500 medical journals as a standard for scientists submitting their research for publication. The three provisions examined were:

— Whether research authors of multiple center clinical trials had access to all trial data;

— Whether research authors or an independent committee controlled the editorial and publication decisions; and

— Whether research investigators were involved in the design and protocol of the studies.

The investigators found academic institution contracts with corporate sponsors rarely included these provisions. Their analyses showed, on average, only 1 percent of these contracts required research authors in multiple center clinical trials to have independent access to data. However, academic institutions coordinating multiple-center studies had a higher level of access in half of the contracts reviewed, researchers report in the October 24 issue of The New England Journal of Medicine.

Lead study author Dr. Kevin A. Schulman, a professor of medicine, said the low compliance rate was a bit of a shock.

“How low the level was kind of surprising and also what was surprising was how powerless the institutions felt in negotiating,” Schulman told United Press International. “There’s a failure of protections.”

Academic centers might feel as though they have minimal power in negotiating better contracts that guarantee freedom from corporate influence and research integrity, Schulman explained. “With a mature industry, this shouldn’t be a threat at all,” Schulman said.

However, a highly competitive environment to find effective drugs tends to make some sponsors unwilling to share control over a project. “I think we will see the academic centers be much more aggressive,” he said. “After our paper comes out, they’ll have a little more ammunition.”

Dr. David Korn, senior vice president for biomedical and health sciences research for the Association of American Medical Colleges in Washington, D.C., said academic centers vary greatly in their size, staff and budget and those factors can affect how they bargain with sponsors.

The finding that compliance was “not 100 percent (is) very troubling,” Korn told UPI. However, he said, there were some flaws in the research approach. “I think the way the study was conducted gives somewhat of a false alarm.”

He added it is standard practice that not all researchers in multiple-center clinical trials have access to the data. “That would be a logistically difficult thing to accomplish on these multi-center trials,” he said, adding it also is standard practice to give access to the data to the coordinating center and lead authors who will have their names appear on the published study. However, not every research team at every single site in these multiple-center studies typically gets to share in that access.

In an accompanying editorial, Dr. Jeffrey M. Drazen, professor of medicine at Harvard School of Public Health in Boston, wrote, “The study by Schulman et al. is imperfect.” Because contract officers were surveyed, Drazen said, considering human nature’s imperfect memory, they are subject to not recalling details correctly. Another flaw, Drazen explained, is research investigators, “who may be more aware of the terms of their contracts than contracting officers,” were not surveyed.

Although there are disagreements about the study’s interpretations, its findings illuminate the delicate power balance between sponsors and academic centers. A report in the same NEJM issue highlights an egregious example between a researcher and a sponsor. The 1998 case involved University of Toronto researcher Nancy Olivieri and Apotex, Inc., a Canadian pharmaceutical firm that funded Olivieri’s research on a drug called deferiprone. When Olivieri found deferiprone ineffective and wanted to publish the results, Apotex halted the clinical trials and threatened legal action.

A similar case occurred around the same time, this time between the University of California, San Francisco and The Immune Response Corp. of Carlsbad, Calif. The dispute was over the effectiveness of an AIDS vaccine. “(Immune Response) objected not to the data, but to how we analyzed the data,” Dr. James Kahn, a professor of medicine at the University of California, San Francisco and principal investigator of that study, told UPI. When UCSF said they did not want to interpret the data differently to make vaccine results more favorable, the company threatened to withhold data and then also threatened legal action. The suit eventually was dropped, Kahn said. The results, which stated the vaccine’s ineffectiveness, were published in the November 1, 2000 issue of Journal of the American Medical Association.

Maximizing results is not a violation of guidelines, however. For complex clinical trials, scientists can publish selected portions of the study, but must note in the publication whether portions of their same research had appeared elsewhere, explained Dr. Steven Lagakos, professor at Harvard’s School of Public Health and an investigator in the AIDS vaccine study funded by Immune Response Corp. “It’s called salami science,” Schulman said, “when you cut the study up into a lot of little pieces”

The problem is one of misrepresenting the data. Data interpretation is key and how the data are interpreted can skew the results of studies called meta-analyses, where researchers combine the results of multiple studies on a single topic. Skewed study results could impact patients.

“Right now we have these mass marketing drugs,” Schulman said, and “the truth is there’s probably a group of patients who probably don’t benefit from some of these classes of drugs.”

Dr. Drummond Rennie, a deputy editor at JAMA and a professor of medicine at the Institute of Health Policy Studies at USCF addressed this issue in an article published in the November 10, 1999 issue of JAMA. Rennie sited an example published in a 1997 issue of British Medical Journal. In that scenario, researchers look at 84 trials involving 11,980 patients to investigate the effective of a drug called ondansetron. Rennie said the researchers found that data from nine clinical trials had been published in 14 reports and that 17 percent of the data was duplicate.

It also turned out data on 28 percent of the total patient population evaluated in the meta-analyses had been reported twice. The biggest point, Rennie noted, is the duplicate data resulted in a 23 percent over-estimation of the efficacy of ondansetron.

“Any study that has strong pharmaceutical backing is highly likely to be defective,” Rennie told UPI. “You get the data the drug company wants you to have.”

Rennie said Schulman’s report began just went ICMJE guidelines had been implemented. “I’m not surprised (by the findings) because this shows what an appalling state everyone was in. It takes years to changes things like this.”

He added, “If the same study was conducted in five years time, I would hope there would be a huge difference.”

(Reported by Katrina Woznicki, UPI Science News, in Washington)

Copyright © 2002 United Press International

FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior general interest in receiving similar information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml If you wish to use copyrighted material for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.

Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.

You may also like

November 21, 2023

Vera Sharav is joining Christine Anderson as special guest for the Make It Your Business event in

Read More
Vera Sharav Joins Christine Anderson for Make It Your Business – Dec 4, 2023 in New Jersey

November 21, 2023

Vera Sharav is premiering the movie Never Again is Now Global in New York City, December 1.

Read More
Never Again is Now Global – Premiere Screening – Dec 1, 2023 in New York City